Prognostic Value of RUNX1 Mutations in AML: A Meta-Analysis

Abstract

<br /> <span style="font-size: small;">The </span><em><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">RUNX1 (AML1) </span></span></em><span style="font-size: small;">gene is a relatively infrequent mutational target in cases of acute myeloid leukemia (AML). Previous work indicated that </span><em><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">RUNX1 </span></span></em><span style="font-size: small;">mutations can have pathological and prognostic implications. To evaluate prognostic value, we conducted a meta-analysis of 4 previous published works with data for survival according to </span><em><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">RUNX1 </span></span></em><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">mutation status. Pooled hazard ratios for overall survival and disease-free survival were 1.55 (95% confidence interval (CI) = 1.11–2.15; p-value = 0.01) and 1.76 (95% CI = 1.24–2.52; p-value = 0.002), respectively, for cases </span></span><span style="font-size: small;">positive for </span><em><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">RUNX1 </span></span></em><span style="font-size: small;">mutations. This evidence supports clinical implications of </span><em><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">RUNX1 </span></span></em><span style="font-size: small;">mutations in the development </span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">and progression of AML cases and points to the possibility of a distinct category within the newer WHO classification. </span></span><span style="font-size: small;">Though it must be kept in mind that the present work was based on data extracted from observational studies, the </span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">findings suggest that the </span></span><em><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">RUNX1 </span></span></em><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">status can contribute to risk-stratification and decision-making in management of AML. </span></span>